INDIA LIVE DESKNIFTY 50:23,140.50(+0.34%)SENSEX:73,895.74(+0.43%)
RDU Global
🇮🇳
🇮🇳 India Edition • Healthcare, Pharma & Life SciencesRDU GLOBAL CORRESPONDENT
VERIFIED WIRE INTELLIGENCE

"Motilal Oswal Sees Aster DM EBITDA Rising 25% CAGR Through FY28, Sets Rs 910 Target"

Motilal Oswal has initiated coverage on Aster DM Quality Care with a Buy rating and a target price of Rs 910, arguing that merger synergies, capacity expansion and improving operating metrics should drive a sustained earnings re-rating. The brokerage expects revenue, EBITDA and PAT to compound at 19.5%, 25% and 33%, respectively, through FY28, placing the hospital chain among the more attractive growth stories in India’s healthcare services space.

Motilal Oswal Sees Aster DM EBITDA Rising 25% CAGR Through FY28, Sets Rs 910 Target

R

RDU Global Wire

Macro Economy & Fiscal Policy Desk

New Delhi, India Just now (12:26 PM IST)•5 min read

Motilal Oswal has initiated coverage on Aster DM Quality Care with a Buy rating and a target price of Rs 910, arguing that merger synergies, capacity expansion and improving operating metrics should drive a sustained earnings re-rating. The brokerage expects revenue, EBITDA and PAT to compound at 19.5%, 25% and 33%, respectively, through FY28, placing the hospital chain among the more attractive growth stories in India’s healthcare services space.

Motilal Oswal has initiated coverage on Aster DM Quality Care with a Buy rating and a target price of Rs 910, arguing that merger synergies, capacity expansion and improving operating metrics should drive a sustained earnings re-rating. The brokerage expects revenue, EBITDA and PAT to compound at 19.5%, 25% and 33%, respectively, through FY28, placing the hospital chain among the more attractive growth stories in India’s healthcare services space.

Editorial & Verification Notice

Reported by RDU Global Correspondent. Formatted and verified using real-time institutional and journalistic wire feeds. Independent reporting adhering to the RDU Global Editorial Code of Conduct.

Related Coverage

Healthcare, Pharma & Life Sciences

Health Ministry Proposes Drug Rules Amendment to Ease Regulation of Medicinal Gases, Empty Gelatin Capsules and Disinfectant Liquids

India’s Health Ministry has proposed amendments to the Drugs Rules, 1945, aimed at introducing greater regulatory flexibility for medicinal gases, empty gelatin capsules and disinfectant liquids. The move signals a broader effort to streamline compliance while preserving quality and safety oversight across essential pharmaceutical inputs.

19 Nov 2026, 05:00 PM IST
Healthcare, Pharma & Life Sciences

Tech Is Powering a Healthier Investment Era as Healthcare Enters a New Digital Age

Healthcare is moving into a new phase in which sensors, wearables, 3D-printed skin, reconstructed organs and data-driven clinical trials are no longer futuristic concepts but investable technologies. For markets and wealth creators, the shift is opening a broad opportunity set across medtech, biotech, diagnostics and digital health, while also raising the bar for regulation, validation and commercial scale.

15 Nov 2026, 08:00 PM IST
Healthcare, Pharma & Life Sciences

India Launches Statewide Drive to Protect Children Against Tetanus and Diphtheria

India has begun a statewide vaccination drive aimed at strengthening protection for children aged 10 and 16 against tetanus and diphtheria, two potentially serious vaccine-preventable diseases. The initiative builds on early-life immunisation coverage, with officials emphasising that the TD vaccine provides an additional shield after children receive Pentavalent vaccines in infancy.

15 Nov 2026, 02:00 PM IST